局部肾上腺素联合直肠吲哚美辛预防高危患者内镜逆行胰胆管造影术后胰腺炎的随机试验
这项多中心、双盲、随机对照试验纳入960例高危患者,比较单用直肠吲哚美辛与联用直肠吲哚美辛和十二指肠乳头局部喷洒肾上腺素预防内镜逆行胰胆管造影术后胰腺炎(PEP)的效果。结果显示,单用组PEP发生率为6.4%,联合组为6.7%,两组无显著差异(P=0.87);严重PEP发生率分别为12%和16%(P=0.88)。结论认为联合局部肾上腺素不能降低高危患者的PEP发生率。
要点
- 高危患者中,单用直肠吲哚美辛组PEP发生率为6.4%,联合局部肾上腺素组为6.7%,无显著差异(P=0.87)。
- 严重PEP在单用组为12%,联合组为16%,无显著差异(P=0.88)。
- 联合局部肾上腺素与单用直肠吲哚美辛相比,未能降低高危患者PEP发生率。
核心结论
- 在高危患者中,与单用直肠吲哚美辛相比,联用直肠吲哚美辛和局部喷洒肾上腺素不能降低PEP的发生率。
研究设计与样本
- 多中心、双盲、随机对照试验,纳入960例高危患者,随机分配至单用直肠吲哚美辛组或联合局部喷洒肾上腺素组,959例完成随访。
主要发现
- 单用直肠吲哚美辛组(n=482)PEP发生率为6.4%,联合组(n=477)为6.7%,P=0.87。
- 严重PEP在单用组有5例(12%),联合组有7例(16%),P=0.88。
- 总体死亡率为0.6%,与主要结局无关。
- 最常见的PEP危险因素为年龄<50岁女性(25.4%)和插管困难(84.9%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rectal indomethacin and topical spray of epinephrine have separately shown efficacy in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) in randomized controlled trials. We hypothesized that the combination of indomethacin and topical spray of epinephrine on the duodenal papillae would further reduce PEP than when indomethacin was used alone. METHODS: We conducted a comparative effectiveness, multicenter, double-blinded, randomized trial of rectal indomethacin alone vs a combination of rectal indomethacin and topical spray of epinephrine for the prevention of PEP in high-risk patients. The primary outcome was the incidence of PEP and the secondary outcome was the severity of PEP. A 2-tailed Fisher's exact test was used to analyze the difference in the proportion of patients with PEP in the indomethacin alone vs the combination group. RESULTS: A total of 960 patients (mean age 52.33 ± 14.96 years; 551 [57.4%] females) were randomized and 959 completed follow-up. The baseline demographic and clinical characteristics were similar between the 2 groups. Women <50 years of age (25.4%) and difficult cannulation (84.9%) were the most common PEP risk factors. The incidence of PEP was 6.4% in the indomethacin alone group (n = 482) compared to 6.7% in the combination group (n = 477; P = 0.87). Severe PEP was found in 5 (12%) and 7 (16%) patients in the indomethacin alone and combination groups, respectively (P = 0.88). The overall mortality was 0.6%, which was unrelated to the primary outcome. CONCLUSIONS: The combination of rectal indomethacin and topical spray of epinephrine does not reduce the incidence of PEP compared to rectal indomethacin alone in high-risk patients; https://clinicaltrials.gov/ct2/show/NCT02116309.
引用
- Kamal A, Akshintala VS, Talukdar R, et al. A Randomized Trial of Topical Epinephrine and Rectal Indomethacin for Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-Risk Patients. Am J Gastroenterol. 2019. PMID: 30730860. doi:10.14309/ajg.0000000000000049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。